Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

For the month ended:	31 October 2022	Status:	New Submission
To : Hong Kong Exchanges	and Clearing Limited		
Name of Issuer:	Innovent Biologics, Inc.		
Date Submitted:	04 November 2022		

I. Movements in Authorised / Registered Share Capital

1. Type of shares	Ordinary shares		Class of shares	Not applicable Listed on SEHK (Note 1) Yes						
Stock code	01801		Description	Ordinary	shares					
		Number o	f authorised/registere	d shares		Par value	9	Auth	orised/registe	red share capital
Balance at close of preceding month			5,000,000,000		USD		0.00001			50,000
Increase / decrease (-)				0				USD		0
Balance at close of the month	1		5,000	,000,000	USD		0.00001	USD		50,000

Total authorised/registered share capital at the end of the month	USD	50,000
---	-----	--------

FF301

II. Movements in Issued Shares

1. Type of shares	Ordinary shares	5	Class of shares	Not applicable	Listed on SEHK (Note 1)	Yes	
Stock code	01801		Description	Ordinary shares			
Balance at close of preceding month		1,530,014,621					
Increase / decrease (-)		2,394,126					
Balance at close of the month		1,532,408,747					

III. Details of Movements in Issued Shares

(A). Share Options (under Share Option Schemes of the Issuer)

1. T	ype of shares issuable	Ordinary shares	Class of shares		Not applica	ble	Shares issuable to be listed on SEHK (Note 1)			Yes		
Stock code of shares issuable (if listed on SEHK) (Note 1)			e 1) 0180:	L								
Pa	articulars of share option scheme	Number of share options outstanding at close of preceding month	Movement during the m		month	Number of share op outstanding at clos the month		No. of new shares of issuer issued during the month pursuant thereto (A)	No. of new share issuer which may issued pursuant th as at close of the r	/ be / ereto	The total numbe securities which m issued upon exerc all share options t granted under t scheme at close o month	ay be tise of to be the
1).	Pre-IPO Share Incentive	33,588,583	Granted			31,59	6,501	492,082	26,9	85,251		0
	Plan		Exercised		-492,082							
			Cancelled		-1,500,000							
			Lapsed									
	neral Meeting approval e (if applicable)	10 May 2012										
2).	Post-IPO share option	49,059,052	Granted			47,80	01,182	376,000	8,4	86,058	63,6	27,888
	scheme		Exercised		-376,000							
			Cancelled		-881,870							
			Lapsed									
	General Meeting approval J2 June 2018											

Total A (Ordinary shares): 868,082

Total funds raised during the month from exercise of options: HKD 11,472,686.38

(B). Warrants to Issue Shares of the Issuer which are to be Listed Not applicable

(D). Any other Agreements or Arrangements to Issue Shares of the Issuer which are to be listed, including Options (other than Share Options Schemes)

1. Ty	ype of shares issuable	Ordinary shares	Class of shares	Not a	pplicable	S	Shares issuable to be listed on SEHK	(Note 1)	Yes	
Stock code of shares issuable (if listed on SEHK) (Note 1) 01801										
Description			General Meeting approval date (if applicable)	No. of new shares of issuer issued during the month pursuant thereto (D) No. of new shares of issuer issued pursuant thereto as month						
1). Innovent Biologics, Inc. 2018 Restricted Share Plan (has been terminated)			15 October 2018	1,489,244				0		
2). Innovent Biologics, Inc. 2020 Restricted Share Plan			12 June 2020		36,800			0		

Total D (Ordinary shares):

1,526,044

(E). Other Movements in Issued Share Not applicable

Total increase / decrease (-) in Ordinary shares	during the month (i.e. Total of A to E)	2,394,126
--	---	-----------

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

V. Confirmations

	o the best knowledge, information and belief that, in relation to each of the securities issued by the issuer during the month as set out in Part III and IV which has not been in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and, insofar as applicable:
(Note 2)	
(i) all money due to	the listed issuer in respect of the issue of securities has been received by it;
(ii) all pre-conditions	for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled;
(iii) all (if any) condit	ions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
(iv) all the securities	of each class are in all respects identical (Note 3);
	quired by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has other legal requirements;
(vi) all the definitive	documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
	taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase or all such property has been duly satisfied; and
(viii) the trust deed/o Registrar of Co	leed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the mpanies.
Submitted by:	Yanju Wang

Title:

Joint Company Secretary

(Director, Secretary or other Duly Authorised Officer)

Notes

1. SEHK refers to Stock Exchange of Hong Kong.

2. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, no further confirmation is required to be made in this return.

- 3. "Identical" means in this context:
 - the securities are of the same nominal value with the same amount called up or paid up;
 - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - . they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
- 4. If there is insufficient space, please submit additional document.
- 5. In the context of repurchase of shares:
 - . "shares issuable to be listed on SEHK" should be construed as "shares repurchased listed on SEHK"; and
 - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares repurchased (if listed on SEHK)"; and
 - . "type of shares issuable" should be construed as "type of shares repurchased"; and
 - . "issue and allotment date" should be construed as "cancellation date"
- 6. In the context of redemption of shares:
 - . "shares issuable to be listed on SEHK" should be construed as "shares redeemed listed on SEHK"; and
 - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares redeemed (if listed on SEHK)"; and
 - . "type of shares issuable" should be construed as "type of shares redeemed"; and
 - . "issue and allotment date" should be construed as "redemption date"